Huaren Pharmaceutical Co Ltd

Huaren Pharmaceutical has completed a key management iteration, fully launched internal governance rectification, cleared historical legacy issues, and optimized its debt structure, opening a new phase of improvement in both governance and performance. The company's 2026 interim report shows steady growth in core kidney disease products, a standout performance in the blood purification segment, coordinated efforts across multiple product lines, and continued expansion of centralized procurement wins. As of the end of the reporting period, the company's total assets were 2.75 billion yuan, net assets were 866 million yuan, and the weighted average return on equity was 3.35 percent, up 0.52 percentage points year on year. In the first half of the year, sales volume of peritoneal dialysis solution reached 17.5573 million bags, with sales revenue of 208 million yuan; sales volume of hemofiltration replacement solution reached 4.3831 million bags, up 38.34 percent year on year, with revenue of 65.6343 million yuan, up 25.75 percent year on year. The company's products have successively won bids in centralized procurement programs in multiple regions, including the Guangdong alliance and the Beijing-Tianjin-Hebei 3+N alliance. Its subsidiary Anhui Hengxing Pharmaceutical's doxofylline injection and levofloxacin injection won bids in the national centralized procurement follow-up program, with actual procurement volumes of 3.6445 million units and 157,500 units respectively. Industry observers believe that this round of governance rectification is a key turning point for the company to resolve historical risks and move forward with a lighter burden, and is expected to unlock both governance value and operational value.